(Q44016349)

29 November 2017

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients (English)

1 reference

29 November 2017

1 reference

1 reference

1

1 reference

29 November 2017

Van Gaal L

2

1 reference

29 November 2017

Usadel KH

3

1 reference

29 November 2017

Ball M

4

1 reference

29 November 2017

Whatmough I

5

1 reference

29 November 2017

Guitard C

6

1 reference

29 November 2017

1 May 2002

1 reference

Diabetes, Obesity and Metabolism

29 November 2017

1 reference

29 November 2017

4

1 reference

29 November 2017

3

1 reference

29 November 2017

177-186

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

29 November 2017

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Rates of hypoglycemia in users of sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Comparative tolerability of sulphonylureas in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2002.00196.X

10.1046/J.1463-1326.2002.00196.X

21 January 2018

Identifiers

DOI

1 reference

release_hnqwznvwt5f3pmirp3uyl57na4

29 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hnqwznvwt5f3pmirp3uyl57na4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference